A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Phase 3Active Not RecruitingNCT06388187

Novo Nordisk A/S300 enrolled

Overview

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

300

Conditions

Obesity

Interventions

CagrilintideDRUG

Participants will receive once-weekly cagrilintide subcutaneously.

SemaglutideDRUG

Participants will receive once-weekly semaglutide subcutaneously.

PlaceboDRUG

Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female * Age above or equal to 18 years at the time of signing informed consent 1. Body Mass index (BMI) greater than or equal to (≥) 30.0 kilogram per meter square (kg/m\^2) or 2. BMI ≥27.0 kg/m2 with the presence of at least one obesity related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening * History of type 1 or type 2 diabetes

Locations (25)

Aurora FDRC Inc.

Costa Mesa, California, United States